X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Natco Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs NATCO PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH NATCO PHARMA PANACEA BIOTECH/
NATCO PHARMA
 
P/E (TTM) x 160.7 29.8 538.3% View Chart
P/BV x 3.6 22.6 15.8% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PANACEA BIOTECH   NATCO PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
NATCO PHARMA
Mar-14
PANACEA BIOTECH/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs149877 17.0%   
Low Rs82424 19.4%   
Sales per share (Unadj.) Rs84.1223.4 37.7%  
Earnings per share (Unadj.) Rs-18.331.1 -58.9%  
Cash flow per share (Unadj.) Rs-6.740.3 -16.6%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs83.7219.5 38.1%  
Shares outstanding (eoy) m61.2533.07 185.2%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x1.42.9 47.2%   
Avg P/E ratio x-6.320.9 -30.1%  
P/CF ratio (eoy) x-17.216.1 -106.8%  
Price / Book Value ratio x1.43.0 46.6%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m7,07421,504 32.9%   
No. of employees `0002.8NA-   
Total wages/salary Rs m1,4491,128 128.5%   
Avg. sales/employee Rs Th1,874.1NM-  
Avg. wages/employee Rs Th527.0NM-  
Avg. net profit/employee Rs Th-407.7NM-  
INCOME DATA
Net Sales Rs m5,1547,389 69.7%  
Other income Rs m100167 59.7%   
Total revenues Rs m5,2547,556 69.5%   
Gross profit Rs m-7661,793 -42.7%  
Depreciation Rs m711304 233.6%   
Interest Rs m1,503366 410.4%   
Profit before tax Rs m-2,8811,290 -223.3%   
Minority Interest Rs m1146 23.3%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17309 5.4%   
Profit after tax Rs m-1,1211,027 -109.1%  
Gross profit margin %-14.924.3 -61.3%  
Effective tax rate %-0.623.9 -2.4%   
Net profit margin %-21.813.9 -156.5%  
BALANCE SHEET DATA
Current assets Rs m3,8103,681 103.5%   
Current liabilities Rs m8,3653,123 267.9%   
Net working cap to sales %-88.47.6 -1,169.2%  
Current ratio x0.51.2 38.6%  
Inventory Days Days15689 174.0%  
Debtors Days Days6759 114.6%  
Net fixed assets Rs m14,4807,685 188.4%   
Share capital Rs m61331 18.5%   
"Free" reserves Rs m9036,670 13.5%   
Net worth Rs m5,1277,259 70.6%   
Long term debt Rs m5,832955 610.7%   
Total assets Rs m19,43311,957 162.5%  
Interest coverage x-0.94.5 -20.3%   
Debt to equity ratio x1.10.1 864.6%  
Sales to assets ratio x0.30.6 42.9%   
Return on assets %2.011.7 16.9%  
Return on equity %-21.914.2 -154.5%  
Return on capital %3.620.7 17.5%  
Exports to sales %24.539.4 62.3%   
Imports to sales %10.25.7 178.6%   
Exports (fob) Rs m1,2642,908 43.5%   
Imports (cif) Rs m525421 124.6%   
Fx inflow Rs m1,5393,445 44.7%   
Fx outflow Rs m942703 134.0%   
Net fx Rs m5972,743 21.8%   
CASH FLOW
From Operations Rs m5991,440 41.6%  
From Investments Rs m-438-1,089 40.2%  
From Financial Activity Rs m-303-353 85.8%  
Net Cashflow Rs m-141-1 9,483.2%  

Share Holding

Indian Promoters % 74.5 52.0 143.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 0.6 7.8 7.7%  
FIIs % 1.3 16.6 7.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 26.0 90.8%  
Shareholders   10,259 25,395 40.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  SANOFI INDIA  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Airtel, Idea Down by 5%(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 24, 2018 02:05 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - PFIZER COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS